333 related articles for article (PubMed ID: 26861657)
21. Deficient Mismatch Repair and the Role of Immunotherapy in Metastatic Colorectal Cancer.
Quiroga D; Lyerly HK; Morse MA
Curr Treat Options Oncol; 2016 Aug; 17(8):41. PubMed ID: 27315067
[TBL] [Abstract][Full Text] [Related]
22. BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy.
Klempner SJ; Gershenhorn B; Tran P; Lee TK; Erlander MG; Gowen K; Schrock AB; Morosini D; Ross JS; Miller VA; Stephens PJ; Ou SH; Ali SM
Cancer Discov; 2016 Jun; 6(6):594-600. PubMed ID: 27048246
[TBL] [Abstract][Full Text] [Related]
23. Characteristics of
de la Fouchardière C; Cohen R; Malka D; Guimbaud R; Bourien H; Lièvre A; Cacheux W; Artru P; François E; Gilabert M; Samalin-Scalzi E; Zaanan A; Hautefeuille V; Rousseau B; Senellart H; Coriat R; Flippot R; Desseigne F; Lardy-Cleaud A; Tougeron D
Oncologist; 2019 Dec; 24(12):e1331-e1340. PubMed ID: 31152084
[TBL] [Abstract][Full Text] [Related]
24. ERK and p38MAPK combine to improve survival in patients with BRAF mutant colorectal cancer.
Roseweir AK; Halcrow ES; Chichilo S; Powell AG; McMillan DC; Horgan PG; Edwards J
Br J Cancer; 2018 Aug; 119(3):323-329. PubMed ID: 29988110
[TBL] [Abstract][Full Text] [Related]
25. Comprehensive analysis of oncogenic fusions in mismatch repair deficient colorectal carcinomas by sequential DNA and RNA next generation sequencing.
Wang J; Li R; Li J; Yi Y; Liu X; Chen J; Zhang H; Lu J; Li C; Wu H; Liang Z
J Transl Med; 2021 Oct; 19(1):433. PubMed ID: 34657620
[TBL] [Abstract][Full Text] [Related]
26. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.
André T; de Gramont A; Vernerey D; Chibaudel B; Bonnetain F; Tijeras-Raballand A; Scriva A; Hickish T; Tabernero J; Van Laethem JL; Banzi M; Maartense E; Shmueli E; Carlsson GU; Scheithauer W; Papamichael D; Möehler M; Landolfi S; Demetter P; Colote S; Tournigand C; Louvet C; Duval A; Fléjou JF; de Gramont A
J Clin Oncol; 2015 Dec; 33(35):4176-87. PubMed ID: 26527776
[TBL] [Abstract][Full Text] [Related]
27. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
[TBL] [Abstract][Full Text] [Related]
28. BRAF-Directed Therapy in Metastatic Colorectal Cancer.
Korphaisarn K; Kopetz S
Cancer J; 2016; 22(3):175-8. PubMed ID: 27341594
[TBL] [Abstract][Full Text] [Related]
29. BRAF V600E mutation detection by immunohistochemistry in colorectal carcinoma.
Affolter K; Samowitz W; Tripp S; Bronner MP
Genes Chromosomes Cancer; 2013 Aug; 52(8):748-52. PubMed ID: 23650027
[TBL] [Abstract][Full Text] [Related]
30. Increased cancer predisposition in family members of colorectal cancer patients harboring the p.V600E BRAF mutation: a population-based study.
Wish TA; Hyde AJ; Parfrey PS; Green JS; Younghusband HB; Simms MI; Fontaine DG; Dicks EL; Stuckless SN; Gallinger S; McLaughlin JR; Woods MO; Green RC
Cancer Epidemiol Biomarkers Prev; 2010 Jul; 19(7):1831-9. PubMed ID: 20570909
[TBL] [Abstract][Full Text] [Related]
31. Clinicopathologic and molecular characteristics of synchronous colorectal cancers: heterogeneity of clinical outcome depending on microsatellite instability status of individual tumors.
Bae JM; Cho NY; Kim TY; Kang GH
Dis Colon Rectum; 2012 Feb; 55(2):181-90. PubMed ID: 22228162
[TBL] [Abstract][Full Text] [Related]
32. Targeting Colon Cancers with Mutated BRAF and Microsatellite Instability.
Matos P; Jordan P
Adv Exp Med Biol; 2018; 1110():7-21. PubMed ID: 30623363
[TBL] [Abstract][Full Text] [Related]
33. Distinct Clinicopathological Patterns of Mismatch Repair Status in Colorectal Cancer Stratified by KRAS Mutations.
Li W; Zhi W; Zou S; Qiu T; Ling Y; Shan L; Shi S; Ying J
PLoS One; 2015; 10(6):e0128202. PubMed ID: 26042813
[TBL] [Abstract][Full Text] [Related]
34. Upfront progression under pembrolizumab followed by a complete response after encorafenib and cetuximab treatment in BRAF V600E-mutated and microsatellite unstable metastatic colorectal cancer patient: A case report.
Gallois C; Taieb J; Sabouret A; Broudin C; Karoui M; Garinet S; Zaanan A
Genes Chromosomes Cancer; 2022 Feb; 61(2):114-118. PubMed ID: 34773327
[TBL] [Abstract][Full Text] [Related]
35. Evolving Strategies for the Management of BRAF-Mutant Metastatic Colorectal Cancer.
Lee HM; Morris V; Napolitano S; Kopetz S
Oncology (Williston Park); 2019 Jun; 33(6):206-11. PubMed ID: 31219603
[TBL] [Abstract][Full Text] [Related]
36. Molecular Evaluation of Colorectal Adenocarcinoma: Current Practice and Emerging Concepts.
Nowak JA; Hornick JL
Surg Pathol Clin; 2016 Sep; 9(3):427-39. PubMed ID: 27523970
[TBL] [Abstract][Full Text] [Related]
37. Reply to the Letter by S. Sorscher Regarding "Implications of BRAF Mutations in dMMR Colorectal Cancers".
Cohen R; André T
Curr Treat Options Oncol; 2017 Sep; 18(10):63. PubMed ID: 28921484
[No Abstract] [Full Text] [Related]
38. RAC1b overexpression correlates with poor prognosis in KRAS/BRAF WT metastatic colorectal cancer patients treated with first-line FOLFOX/XELOX chemotherapy.
Alonso-Espinaco V; Cuatrecasas M; Alonso V; Escudero P; Marmol M; Horndler C; Ortego J; Gallego R; Codony-Servat J; Garcia-Albeniz X; Jares P; Castells A; Lozano JJ; Rosell R; Maurel J
Eur J Cancer; 2014 Jul; 50(11):1973-81. PubMed ID: 24833563
[TBL] [Abstract][Full Text] [Related]
39. BRAF-Mutated Colorectal Cancer Exhibits Distinct Clinicopathological Features from Wild-Type BRAF-Expressing Cancer Independent of the Microsatellite Instability Status.
Jang MH; Kim S; Hwang DY; Kim WY; Lim SD; Kim WS; Hwang TS; Han HS
J Korean Med Sci; 2017 Jan; 32(1):38-46. PubMed ID: 27914130
[TBL] [Abstract][Full Text] [Related]
40. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
László L
Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]